Formulation Development
ReciBioPharm Partners With Acuitas Therapeutics to Provide Rapid Technology Transfers & cGMP Manufacture of LNP Formulations
ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, and biotechnology firm Acuitas Therapeutics have recently announced they are taking their partnership to the next level….
Athira Pharma Announces Encouraging Results From SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia & Dementia With Lewy Bodies
Athira Pharma, Inc. recently announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton (ATH-1017) in patients with Parkinson’s disease dementia and dementia…
ADMA Biologics Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age & Older
ADMA Biologics, Inc. recently announced the US FDA has approved the company’s supplemental Biologics License Application submitted under section 351(a) of the Public Health Service…
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering Corporation recently announced the US FDA has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate…
Abzena Partners With ProteoNic to Offer Enhanced CHO Cell Line
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO, recently announced a partnership with ProteoNic Biosciences BV to license their premium protein expression….
Coya Therapeutics & Dr. Reddy’s Laboratories Enter Development & Commercialization Agreement for ALS Treatment
Dr. Reddy’s Laboratories SA and Coya Therapeutics, Inc. recently announced they have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for….
AbbVie Announces FDA & EMA Updates for Epcoritamab for the Treatment of Relapsed/Refractory Follicular Lymphoma
AbbVie recently announced updates from the US FDA and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed…
Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding….
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 & ELAINE-2 Trial Results
Sermonix Pharmaceuticals Inc. recently announced results of its two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies were published in Annals of Oncology,…
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control & Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells
Sana Biotechnology, Inc. recently announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP)…
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint0Resistant Metastatic Melanoma Phase 1 Trial
TILT Biotherapeutics recently presented safety and efficacy data from its international Phase 1 trial in patients with metastatic melanoma (NTC04217473), in an oral presentation at…
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen & Ultevursen Ophthalmic Assets
Agreement provides ProQR with initial payment of €8M and up to €165M in earn-out payments, as well as potential double-digit royalties based on commercial sales in the US and EU….
Rigel Pharmaceuticals & MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML & Other Cancers
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center (MD Anderson) recently announced a multi-year strategic development collaboration to expand the evaluation…
IMIDomics & Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research & Development
IMIDomics recently announced it is expanding its strategic collaboration with Bristol Myers Squibb that extends the existing relationship between the two companies, advancing their shared commitment to….
ONK Therapeutics & NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies & FLEX-NK Bispecific Antibodies
ONK Therapeutics and NAYA Biosciences Inc. announced they have entered into a research partnership to evaluate combination therapy consisting of ONK’s optimally engineered natural….
Incannex Provides Update on Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
Incannex Healthcare Inc. recently provided the following update on its proprietary IHL-42X drug candidate. Obstructive sleep apnea (OSA) is characterized by a narrowing or obstruction…
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting With FDA for Rosacea Treatment
Journey Medical Corporation recently announced it received the official meeting minutes from its pre-New Drug Application (NDA) meeting with the FDA for DFD-29 (Minocycline Hydrochloride…
Recipharm Announces Collaboration With Oz-UK to Accelerate the Development of Low Global Warming Potential pMDIs Utilizing HFA-152a Propellant
Recipharm recently announced a collaboration with Oz-UK to accelerate the development and manufacture of “green” pressurized metered dose inhalers (pMDIs). The pMDIs will utilize valves…
Curia Recognized on India Pharma Outlook’s 2023 List of Top 10 CDMO Companies in India
Curia recently announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be…
Rumi Scientific Announces Partnership With X-Chem for Development of Lead Candidate in Huntington’s Disease
Rumi Scientific recently announced it has entered into a partnership with X-Chem through which X-Chem will develop a lead candidate BRD9 inhibitor for the treatment…
